2 major innovations in allogeneic cell therapy

Impacts

Technological impact

• Innovative bioproduction using non-modified human GFs decreases production costs to allow greater patient access to effective allogeneic cell therapy

Clinical impact

•A unique combination of anti-inflammatory and tissue repair properties via immune tolerance may allow for new treatments to be created for many diseases, such as inflammatory and tissue repair disorders.

Social impact

• Scarcell Therapeutics' goal is to provide an effective new regenerative therapy at a lower cost

Environmental impact

• Environmentally friendly bioproduction process
• May reduce drug consumption

Scarcell therapeutics collaborates with a network of renowned partners and institutional bodies

The production process is developed in partnership with CDMOs

Scarcell Therapeutics is supported by the following clusters and Bpifrance.

Scarcell Therapeutics is privately funded and has been granted non-dilutive funding from the French government (France 2030) and the European Union (Next Generation EU).